Boston Therapeutics, Inc. (BTHE)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Boston Therapeutics, Inc. (BTHE) with AI Score 43/100 (Weak). Boston Therapeutics, Inc. is a pharmaceutical development company focused on carbohydrate-based therapeutics and dietary supplements. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Boston Therapeutics, Inc. (BTHE) Healthcare & Pipeline Overview
Boston Therapeutics, Inc. is a pre-clinical and clinical-stage pharmaceutical company developing carbohydrate-based therapies, including BTI-320 for diabetes management. The company also offers the SUGARDOWN dietary supplement, operating within the competitive biotechnology sector focused on innovative treatments for metabolic disorders.
Investment Thesis
Boston Therapeutics operates in the high-growth biotechnology sector, focusing on innovative treatments for diabetes and related complications. The company's lead drug candidate, BTI-320, is in Phase IIb clinical trials, representing a potential near-term catalyst. Positive trial results could significantly increase the company's valuation. The market for diabetes treatments is substantial, with a growing prevalence of Type 2 diabetes globally. However, the company faces significant risks, including the need for further funding to complete clinical trials and the uncertainty of regulatory approval. The negative profit margin of -9724.5% and gross margin of -243.2% highlight the company's current unprofitability and reliance on external funding. The company's beta of -0.78 suggests a low correlation with the overall market, which may appeal to risk-averse investors. Successful commercialization of BTI-320 or other pipeline products is critical for the company's long-term viability.
Based on FMP financials and quantitative analysis
Key Highlights
- BTI-320 is in Phase IIb clinical trials targeting post-meal blood glucose levels in Type 2 diabetes and pre-diabetic patients.
- BTI-410 has completed Phase Ib clinical trials for type 1 immunosuppression therapy and type 2 diabetes patients.
- IPOXYN is a carbohydrate-based injectable drug to prevent necrosis and treat hypoxic conditions.
- SUGARDOWN is a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose.
- The company's P/E ratio is -1.22, reflecting its current lack of profitability.
Competitors & Peers
Strengths
- Novel carbohydrate-based drug platform.
- Lead drug candidate in Phase IIb clinical trials.
- Existing dietary supplement product (SUGARDOWN).
- Experienced management team.
Weaknesses
- Limited financial resources.
- Negative profit margin and gross margin.
- Reliance on external funding.
- OTC market listing.
Catalysts
- Upcoming: Results from Phase IIb clinical trials for BTI-320 expected in late 2026.
- Ongoing: Continued sales and marketing efforts for SUGARDOWN dietary supplement.
- Ongoing: Potential partnerships with pharmaceutical companies for drug development.
Risks
- Potential: Failure to secure additional funding for clinical trials.
- Potential: Regulatory approval delays or rejection of drug candidates.
- Ongoing: Competition from established diabetes treatments.
- Ongoing: Patent expiration and generic competition.
- Ongoing: Negative profit margin and reliance on external funding.
Growth Opportunities
- Successful completion of Phase IIb clinical trials for BTI-320 represents a significant growth opportunity. Positive results could lead to partnerships with larger pharmaceutical companies or potential acquisition. The market for diabetes treatments is estimated to reach $400 billion by 2028, providing a substantial addressable market for BTI-320. The timeline for potential commercialization is dependent on the clinical trial outcomes and regulatory approval, potentially within the next 3-5 years.
- Development and commercialization of IPOXYN for the treatment of diabetic foot ulcers and other hypoxic conditions offers another growth avenue. Diabetic foot ulcers are a significant complication of diabetes, affecting millions of patients worldwide. The market for wound care products is estimated at $22 billion, with a growing demand for advanced therapies. The timeline for IPOXYN's development depends on preclinical and clinical trial progress, potentially reaching the market in 5-7 years.
- Expansion of the SUGARDOWN dietary supplement market represents a more immediate growth opportunity. The dietary supplement market is less regulated than pharmaceuticals, allowing for faster commercialization. The market for blood glucose management supplements is estimated at $5 billion, with a growing consumer interest in natural and non-prescription options. Boston Therapeutics can leverage its existing distribution channels and marketing efforts to increase SUGARDOWN sales within the next 1-2 years.
- Strategic partnerships with academic institutions and research organizations can accelerate the development of new product candidates. Collaborations can provide access to novel technologies and expertise, reducing the company's reliance on internal research and development. These partnerships can lead to the discovery of new therapeutic targets and the development of innovative treatments for diabetes and related complications. The timeline for these partnerships to yield tangible results is variable, ranging from 2-5 years.
- Securing additional funding through grants, venture capital, or public offerings is crucial for the company's long-term growth. Access to capital will enable Boston Therapeutics to advance its clinical trials, expand its research and development efforts, and commercialize its product candidates. The company's ability to attract funding will depend on its clinical trial results, market potential, and management team. The timeline for securing additional funding is ongoing, with the company continuously seeking opportunities to strengthen its financial position.
Opportunities
- Successful completion of clinical trials.
- Partnerships with larger pharmaceutical companies.
- Expansion of SUGARDOWN market.
- Development of new product candidates.
Threats
- Regulatory approval delays.
- Competition from established diabetes treatments.
- Patent expiration.
- Failure to secure additional funding.
Competitive Advantages
- Proprietary carbohydrate-based drug formulations.
- Patent protection for key drug candidates.
- Clinical trial data demonstrating efficacy.
- Established brand recognition for SUGARDOWN dietary supplement.
- Expertise in carbohydrate chemistry and drug development.
About BTHE
Founded in 2009 and headquartered in Lawrence, Massachusetts, Boston Therapeutics, Inc. is a pharmaceutical development company focused on developing, manufacturing, and commercializing carbohydrate-based therapeutic drugs and dietary supplements. Originally named Avanyx Therapeutics, Inc., the company changed its name in November 2010. Boston Therapeutics' lead product candidate is BTI-320, a non-systemic carbohydrate-based compound currently in Phase IIb clinical trials. BTI-320 aims to reduce post-meal blood glucose elevation in patients with Type 2 diabetes and pre-diabetes. The company is also developing BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients. Additionally, Boston Therapeutics is working on IPOXYN, a carbohydrate-based injectable drug designed to prevent necrosis and treat hypoxic conditions, such as diabetic foot ulcers. The company also markets SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy post-meal blood glucose levels. Boston Therapeutics operates primarily in the United States, targeting the large and growing market for diabetes treatments and dietary supplements.
What They Do
- Develop carbohydrate-based therapeutic drugs.
- Focus on treatments for Type 2 diabetes and pre-diabetes.
- Conduct clinical trials for drug candidates like BTI-320 and BTI-410.
- Develop injectable drugs to prevent necrosis and treat hypoxic conditions.
- Manufacture and sell the SUGARDOWN dietary supplement.
- Research and develop therapies for diabetic foot ulcers and vascular complications.
- Seek regulatory approvals for pharmaceutical products.
Business Model
- Develop and patent novel carbohydrate-based therapeutic drugs.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from the FDA for commercialization.
- Manufacture and market pharmaceutical products and dietary supplements.
- Generate revenue through product sales and potential licensing agreements.
Industry Context
Boston Therapeutics operates within the biotechnology industry, a sector characterized by high growth potential and significant risk. The global market for diabetes treatments is substantial and growing, driven by the increasing prevalence of the disease. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms developing novel therapies. Boston Therapeutics focuses on carbohydrate-based therapeutics, a niche area within the broader diabetes market. The company's success depends on its ability to successfully navigate the regulatory approval process and commercialize its product candidates. Competitors include AVEFF, BNOEF, FLWPF, FWPAY, and HBCNF, each pursuing different approaches to diabetes treatment and management.
Key Customers
- Patients with Type 2 diabetes and pre-diabetes.
- Healthcare providers prescribing diabetes treatments.
- Consumers seeking dietary supplements for blood glucose management.
- Hospitals and clinics treating diabetic foot ulcers.
- Patients undergoing kidney transplant surgery (for BTI-410).
Financials
Chart & Info
Boston Therapeutics, Inc. (BTHE) stock price: Price data unavailable
Latest News
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BTHE.
Price Targets
Wall Street price target analysis for BTHE.
MoonshotScore
What does this score mean?
The MoonshotScore rates BTHE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Chi-Heng Cheng
CEO
Chi-Heng Cheng serves as the CEO of Boston Therapeutics, Inc. His background includes experience in the pharmaceutical and biotechnology industries. Specific details regarding his educational background and previous roles are not available in the provided source data. However, as CEO, he is responsible for the overall strategic direction and operational management of the company.
Track Record: Information on Chi-Heng Cheng's specific achievements and strategic decisions as CEO of Boston Therapeutics, Inc. is not available in the provided source data. Therefore, a detailed assessment of his track record cannot be provided.
BTHE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Boston Therapeutics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on the OTC Other tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with distressed financials, early-stage ventures, or those that choose not to comply with stricter listing requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other listing.
- Lower trading volume and liquidity compared to major exchanges.
- Potential for price volatility and manipulation.
- Increased risk of fraud or mismanagement.
- Difficulty in obtaining accurate and timely information.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Presence of a physical headquarters and operational facilities.
- Development of pharmaceutical drug candidates in clinical trials.
- Sales of the SUGARDOWN dietary supplement.
- Experienced management team with relevant industry expertise.
- Independent auditor review of financial statements (if available).
What Investors Ask About Boston Therapeutics, Inc. (BTHE)
What does Boston Therapeutics, Inc. do?
Boston Therapeutics, Inc. is a pharmaceutical development company focused on developing carbohydrate-based therapeutics and dietary supplements. Their primary focus is on treatments for Type 2 diabetes and pre-diabetes, with their lead drug candidate, BTI-320, currently in Phase IIb clinical trials. The company also develops injectable drugs for diabetic foot ulcers and markets the SUGARDOWN dietary supplement for blood glucose management, aiming to provide innovative solutions for metabolic disorders.
What do analysts say about BTHE stock?
Analyst coverage of Boston Therapeutics (BTHE) is limited due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio (-1.22) and profit margin (-9724.5%), reflect the company's current lack of profitability. Growth considerations center on the successful completion of clinical trials for BTI-320 and potential partnerships. However, the company faces significant risks, including funding constraints and regulatory hurdles. A neutral summary would emphasize the speculative nature of the investment and the need for further due diligence.
What are the main risks for BTHE?
The main risks for Boston Therapeutics include the uncertainty of clinical trial outcomes for BTI-320, which is crucial for its future prospects. Securing additional funding is also a significant risk, as the company currently operates with a negative profit margin. Regulatory approval delays or rejection by the FDA could severely impact the company's valuation. Competition from established diabetes treatments and potential patent expiration also pose ongoing threats to its long-term success.
How does Boston Therapeutics, Inc. navigate regulatory approval processes?
As a clinical-stage pharmaceutical company, Boston Therapeutics, Inc. must adhere to stringent regulatory requirements set by the FDA. The company's strategy involves conducting rigorous preclinical and clinical trials to demonstrate the safety and efficacy of its drug candidates, such as BTI-320. They must compile comprehensive data packages for submission to the FDA, addressing all aspects of drug development, manufacturing, and quality control. Successful navigation of these processes is critical for obtaining market approval and commercializing their products.
How does Boston Therapeutics, Inc. manage patent expiration risks?
Boston Therapeutics, Inc. manages patent expiration risks by actively seeking patent protection for its novel carbohydrate-based drug formulations and therapeutic applications. They strategically file patent applications to cover various aspects of their inventions, including composition of matter, methods of use, and manufacturing processes. Furthermore, the company may explore strategies such as developing new formulations or indications for existing drugs to extend their market exclusivity beyond the initial patent term. Proactive management of intellectual property is essential for maintaining a competitive advantage in the pharmaceutical industry.
What are the key factors to evaluate for BTHE?
Boston Therapeutics, Inc. (BTHE) currently holds an AI score of 43/100, indicating low score. Key strength: Novel carbohydrate-based drug platform.. Primary risk to monitor: Potential: Failure to secure additional funding for clinical trials.. This is not financial advice.
How frequently does BTHE data refresh on this page?
BTHE prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BTHE's recent stock price performance?
Recent price movement in Boston Therapeutics, Inc. (BTHE) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel carbohydrate-based drug platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for CEO track record.
- OTC market carries higher risk than major exchanges.
- Financial data reflects current unprofitability.